Literature DB >> 10430110

Effect of dexamethasone on reactive oxygen species generation by leukocytes and plasma interleukin-10 concentrations: a pharmacodynamic study.

P Dandona1, P Mohanty, W Hamouda, A Aljada, Y Kumbkarni, R Garg.   

Abstract

After the demonstration that hydrocortisone inhibits reactive oxygen species (ROS) generation by leukocytes in vivo in a highly predictable manner, we investigated the effect of dexamethasone at a dose of 4 mg, which is thought to be roughly equivalent to 100 mg hydrocortisone. We also tested the hypothesis that dexamethasone may increase the plasma concentration of interleukin-10 (IL-10), an immunomodulatory cytokine that inhibits T(H)1 cells. Dexamethasone (4 mg given intravenously) markedly inhibited ROS generation by mononuclear cells and polymorphonuclear leukocytes. The onset of the effect on polymorphonuclear leukocytes occurred at 1 hour (76.3% +/- 9.3% of basal value), and the peak effect occurred at 4 hours (22.9% +/- 6.4% of basal value), with a significant inhibition still persistent at 8 hours (51.3% +/- 14.3% of basal value; F = 66.7; P < .001). ROS generation was restored to baseline at 24 hours (97.6% +/- 9.5%). The inhibitory effect of dexamethasone on mononuclear cells was 78.3% +/- 9.5% of baseline at 1 hour, 11.4% +/- 6.6% at 4 hours, 30.3% +/- 14.1% at 8 hours, and 102.3% +/- 18% at 24 hours (F = 66.5; P < .001). The peak inhibitory effect of dexamethasone on mononuclear cells (11.4% +/- 6.6%) was significantly greater (P < .05) than that on polymorphonuclear leukocytes (22.9% +/- 6.4%). Plasma IL-10 concentrations increased consistently from 4.8 +/- 1.8 pg/mL within 1 hour of dexamethasone injection and peaked at 4 hours (8.8 +/- 2.3 pg/mL), declining to baseline at 8 hours (F = 4.26; P < .004). Dexamethasone (and possibly other glucocorticoids) therefore exerts its immunosuppressive and anti-inflammatory effects by inhibiting ROS generation by leukocytes and by increasing the plasma concentrations of IL-10.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430110     DOI: 10.1016/S0009-9236(99)70054-8

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  26 in total

Review 1.  Meta-analysis of adjunctive dexamethasone to improve clinical outcome of bacterial meningitis in children.

Authors:  Ying Wang; Xinjie Liu; Yuzhen Wang; Qi Liu; Cuicui Kong; Guixia Xu
Journal:  Childs Nerv Syst       Date:  2017-11-29       Impact factor: 1.475

2.  Effects of dexamethasone on aquaporin-4 expression in brain tissue of rat with bacterial meningitis.

Authors:  Kai-Xian Du; Yan Dong; Yan Zhang; Li-Wei Hou; Dong-Xia Fan; Yu Luo; Xiao-Li Zhang; Tian-Ming Jia; Ji-Yu Lou
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  Expression and function of MIP-2 are reduced by dexamethasone treatment in vivo.

Authors:  R Schramm; Q Liu; H Thorlacius
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 4.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

5.  Dexamethasone protects cultured rat hepatocytes against cadmium toxicity: involvement of cellular thiols.

Authors:  Andrea Ferrigno; Cesarina Gregotti; Plinio Richelmi; Mariapia Vairetti
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-12-08       Impact factor: 2.416

6.  In vivo assessment of respiratory burst inhibition by xenobiotic exposure using larval zebrafish.

Authors:  Drake W Phelps; Ashley A Fletcher; Ivan Rodriguez-Nunez; Michele R Balik-Meisner; Debra A Tokarz; David M Reif; Dori R Germolec; Jeffrey A Yoder
Journal:  J Immunotoxicol       Date:  2020-12       Impact factor: 3.000

7.  Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis.

Authors:  Soumen Bera; Suzanne Greiner; Amit Choudhury; Angela Dispenzieri; Douglas R Spitz; Stephen J Russell; Apollina Goel
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

8.  Dexamethasone, a drug for attenuation of Schistosoma mansoni infection morbidity.

Authors:  Alexandre dos Santos Pyrrho; Juliene Antonio Ramos; Roberto Moura Neto; Célia Santos da Silva; Henrique Leonel Lenzi; Christina Maeda Takiya; Cerli Rocha Gattass
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

9.  Using Radiolabeled 3'-Deoxy-3'-18F-Fluorothymidine with PET to Monitor the Effect of Dexamethasone on Non-Small Cell Lung Cancer.

Authors:  Christopher I McHugh; Monica R Thipparthi; Jawana M Lawhorn-Crews; Lisa Polin; Shirish Gadgeel; Janice Akoury; Thomas J Mangner; Kirk A Douglas; Jing Li; Manohar Ratnam; Anthony F Shields
Journal:  J Nucl Med       Date:  2018-04-19       Impact factor: 10.057

10.  Safety and feasibility of adjunctive dexamethasone infusion into the adventitia of the femoropopliteal artery following endovascular revascularization.

Authors:  Christopher D Owens; Warren J Gasper; Joy P Walker; Hugh F Alley; Michael S Conte; S Marlene Grenon
Journal:  J Vasc Surg       Date:  2014-01-11       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.